Zobrazeno 1 - 3
of 3
pro vyhledávání: '"on behalf of the FUTURE 2 study group"'
Autor:
L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Abstract Background Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psor
Externí odkaz:
https://doaj.org/article/0dd60651da2b4233be2757c232a6e70f
Autor:
Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-9 (2018)
Abstract Background Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including
Externí odkaz:
https://doaj.org/article/3198b9481c9148638efdc4f89979257b
Autor:
McInnes, Iain B., Mease, Philip J., Schett, Georg, Kirkham, Bruce, Strand, Vibeke, Williams, Nicole, Fox, Todd, Pricop, Luminita, Jugl, Steffen M., Gandhi, Kunal K., on behalf of the FUTURE 2 Study Group
Publikováno v:
Arthritis Research & Therapy; 6/7/2018, Vol. 20 Issue 1, pN.PAG-N.PAG, 1p